Emerging data indicate that TGF-ss signaling in both epithelial cells and fibroblasts, in addition to controlling cell proliferation, also regulates the microenvironment by modulating the expression of growth factors, chemokines and cytokines. Loss of TGF-ss signaling in both mammary epithelial cells and stromal fibroblasts can result in increased production of chemokines that recruit bone marrow-derived cells (BMDCs), which then influence the initiation and progression of carcinomas. By conditional knockout of the type II TGFss receptor gene (Tgfbr2) in a subset of tissue fibroblasts using FSP1-Cre (Tgfbr2FSPKO), we have shown that loss of TGF-ss signaling enhances the initiation and progression of carcinomas in adjacent epithelia. Because of the short life span of the homozygous Tgfbr2FSPKO animals, we have employed recombination of Tgfbr2FSPKO and control mammary fibroblasts with mouse mammary carcinoma cells that are transplanted beneath the renal capsule of nude mice. The results of these studies show that Tgfbr2FSPKO fibroblasts enhance carcinoma growth, invasion and metastasis. Mechanisms identified so far include increased secretion of HGF, MSP and TGF-? by Tgfbr2FSPKO fibroblasts relative to control fibroblasts with increased activating phosphorylation of cognate receptors on adjacent carcinoma cells. Inhibition of c-Met attenuates the effects of the Tgfbr2FSPKO fibroblasts. Further, the Tgfbr2FSPKO fibroblasts secrete increased levels of several chemokines with associated increased infiltration of BMDCs that are known to promote carcinoma progression. Based on these observations and other data, we hypothesize that TGF-ss signaling in a subset of mammary gland fibroblasts is tumor suppressive for adjacent epithelia by regulating expression of growth factors, cytokines and chemokines. As a corollary, altered TGF-ss signaling in these stromal cells enhances mammary carcinoma initiation and progression by regulating secretion of both selected growth factors (i.e., HGF, MSP, TGF-?) that act in a paracrine manner on the epithelial cells and chemokines that recruit BMDCs to the tumor site. The BMDCs in turn express high levels of TGF-ss and MMPs that further promote tumor progression. These hypotheses can only be tested in animal models, and we will examine them through the following specific aims.
Specific aim 1. Determine the effect of TGF-ss signaling in different subsets of mammary fibroblasts on mammary gland development and oncogene-induced mammary carcinomas.
Specific aim 2. Determine mechanisms and effects of recruitment of BMDC caused by Tgfbr2 knockout in different subsets of fibroblasts on mammary carcinoma initiation and progression.
Specific aim 3. Determine whether altered mammary fibroblast TGF-ss signaling contributes to progression of human breast cancer.

Public Health Relevance

Increasing evidence, a significant amount derived from work supported by this grant, indicates that TGF-beta signaling in stromal fibroblasts can play a significant role in the initiation and progression of carcinomas. This resubmission application proposes to investigate the role of TGF-beta signaling in regulating chemokine expression, recruitment of immature bone marrow-derived cells to the tumor microenvironment, and the effect of these cells on tumor initiation and progression. This work will identify new targets for cancer therapy.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Tumor Progression and Metastasis Study Section (TPM)
Program Officer
Mohla, Suresh
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Vanderbilt University Medical Center
Anatomy/Cell Biology
Schools of Medicine
United States
Zip Code
Lehmann, Brian D; Jovanovi?, Bojana; Chen, Xi et al. (2016) Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection. PLoS One 11:e0157368
Shaw, Aubie K; Pickup, Michael W; Chytil, Anna et al. (2015) TGF? signaling in myeloid cells regulates mammary carcinoma cell invasion through fibroblast interactions. PLoS One 10:e0117908
Hover, Laura D; Young, Christian D; Bhola, Neil E et al. (2015) Small molecule inhibitor of the bone morphogenetic protein pathway DMH1 reduces ovarian cancer cell growth. Cancer Lett 368:79-87
Pickup, Michael W; Hover, Laura D; Polikowsky, Eleanor R et al. (2015) BMPR2 loss in fibroblasts promotes mammary carcinoma metastasis via increased inflammation. Mol Oncol 9:179-91
Owens, P; Pickup, M W; Novitskiy, S V et al. (2015) Inhibition of BMP signaling suppresses metastasis in mammary cancer. Oncogene 34:2437-49
Pickup, Michael W; Hover, Laura D; Guo, Yan et al. (2015) Deletion of the BMP receptor BMPR1a impairs mammary tumor formation and metastasis. Oncotarget 6:22890-904
Ryzhov, Sergey V; Pickup, Michael W; Chytil, Anna et al. (2014) Role of TGF-? signaling in generation of CD39+CD73+ myeloid cells in tumors. J Immunol 193:3155-64
Novitskiy, Sergey V; Forrester, Elizabeth; Pickup, Michael W et al. (2014) Attenuated transforming growth factor beta signaling promotes metastasis in a model of HER2 mammary carcinogenesis. Breast Cancer Res 16:425
Jovanovi?, Bojana; Beeler, J Scott; Pickup, Michael W et al. (2014) Transforming growth factor beta receptor type III is a tumor promoter in mesenchymal-stem like triple negative breast cancer. Breast Cancer Res 16:R69
Pickup, Michael; Novitskiy, Sergey; Moses, Harold L (2013) The roles of TGF? in the tumour microenvironment. Nat Rev Cancer 13:788-99

Showing the most recent 10 out of 40 publications